Classifying Hepatitis B Therapies with Insights from Covalently Closed Circular DNA Dynamics

Jie-Li Hu,Ai-Long Huang

DOI: https://doi.org/10.1016/j.virs.2023.12.005

IF: 6.947

2023-12-18

Virologica Sinica

Abstract:Highlights • HBV replicates in a closed-loop pattern without a defined beginning or end. • cccDNA is the key rate-limiting node in this loop that must be cleared to eliminate HBV. • Anti-HBV strategies can be classified into two categories based on their impact on cccDNA dynamics. • Accelerating cccDNA decay is essential to cure chronic hepatitis B. The achievement of a functional cure for chronic hepatitis B (CHB) remains limited to a minority of patients treated with currently approved drugs. The primary objective in developing new anti-HBV drugs is to enhance the functional cure rates for CHB. A critical prerequisite for the functional cure of CHB is a substantial reduction, or even eradication of covalently closed circular DNA (cccDNA). Within this context, the changes in cccDNA levels during treatment become as a pivotal concern. We have previously analyzed the factors influencing cccDNA dynamics and introduced a preliminary classification of hepatitis B treatment strategies based on these dynamics. In this review, we employed a systems thinking perspective to elucidate the fundamental aspects of the HBV replication cycle and to rationalize the classification of treatment strategies according to their impact on the dynamic equilibrium of cccDNA. Building upon this foundation, we categorize current anti-HBV strategies into two distinct groups and advocate for their combined use to significantly reduce cccDNA levels within a well-defined timeframe.

virology